Now significantly having outgrown the SBIR space, Albany Molecular Research, Inc. (AMRI) is a contract research and manufacturing company providing fully integrated drug discovery, development and manufacturing services. The firm operates through three segments: Discovery and Development Services (DDS), API, and Drug Product. The DDS segment offers services from target identification tools to investigational new drug enabling activities, such as diverse chemistry library design and synthesis, medicinal chemistry, biology, and pharmacology, including drug metabolism and pharmacokinetics. It also provides analytical chemistry services for drug discovery, and pharmaceutical development and manufacturing; and chemical development technologies to promote the solutions for route development from late lead optimization to commercial manufacturing. The API segment offers chemical synthesis and manufacturing services in accordance with current good manufacturing practices (cGMP) regulations. The Drug Product segment provides integrated pharmaceutical drug development programs and services, including process research and development, pre-formulation and formulation development, and GLP bioanalytical and separation sciences. It also offers formulation development services for solid dosage, solution, suspension, topicals, and injectables; cGMP early clinical phase capsules filling and cGMP early clinical powder in bottle for solution and suspension. In addition, this segment provides cGMP contract manufacturing services in sterile syringe and vial filling using specialized technologies, including lyophilization. The company serves pharmaceutical and biotechnology companies; government research entities and non-profit organizations; and agriculture, fine chemicals, contract chemical manufacturing, medical devices, and flavoring and cosmetics businesses. The firm has a strategy of acquisition having acquired eight firm, two in 2016 alone
